查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587514

韓特氏症治療市場規模、佔有率和趨勢分析報告：按類型、給藥途徑、最終用途、地區和細分市場預測，2025-2030年

Hunter Syndrome Treatment Market Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), By Route Of Administration, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

韓特氏症治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球韓特氏症治療市場規模將達17.8億美元，2025年至2030年複合年成長率為5.3%。

大量未滿足的需求、強大的產品線、對這種罕見疾病的認知不斷提高，以及開拓新治療方法的研發活動的活性化，預計將在預測期內推動市場成長。

韓特氏症，也稱為 II 型黏多醣症(MPS II)，是一種罕見的遺傳性疾病，由艾杜醣醛酸-2-硫酸酯酶缺陷或功能障礙所引起。根據美國神經病變和中風研究所公佈的資料，每 10 萬至 15 萬男新生兒中就有 1 人患有 MPS II 症候群。

目前尚無核准的韓特氏症治療方法。可用的治療方案，例如酵素替代療法（ERT）和造血幹細胞移植（HSCT），重點是隨著疾病的進展緩解症狀並控制併發症。 Shire 的 Elaprase（idursulfase）是全球唯一可用於治療韓特氏症的主要藥物，GC Pharma 的 Hunterase（idursulfase beta）僅在韓國核准。

主要公司專注於廣泛的研究和開發活動，以開發產品並獲得新療法的核准。此類新治療藥物的推出預計將在不久的將來顯著加速韓特氏症治療市場的成長。例如，2018年5月，REGENXBIO Inc.的候選藥物RGX-121獲得美國FDA的簡審類，該藥物適用於治療相同疾病。

韓特氏症治療市場報告亮點

  • 靜脈注射將引領市場，到2024年將佔據最大的銷售佔有率，達到72.3%。
  • 酵素替代療法（ERT）因其能夠解決艾杜醣醛酸-2-硫酸酯酶缺陷的能力而引領市場，2024年佔最大收益佔有率為57.3%。
  • 該市場以醫院為主，由於其提供全面護理的能力和先進的醫療資源，醫院在2024年佔據最大的收益佔有率，達到63.1%。
  • 北美韓特氏症治療市場主導全球市場，2024年佔最大銷售佔有率，達37.5%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章韓特氏症治療市場變數、趨勢、範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章韓特氏症治療市場：按類型分類的業務分析

  • 2024 年和 2030 年按類型分類的市場佔有率
  • 類型細分儀表板
  • 2018-2030 年按類型分類的市場規模、預測與趨勢分析
  • 酵素替代療法（ERT）
  • 造血幹細胞移植（HSCT）
  • 其他

第5章韓特氏症治療市場：依給藥途徑的業務分析

  • 2024 年及 2030市場佔有率給藥途徑途徑
  • 途徑細分儀表板
  • 2018-2030 年按管理途徑的市場規模、預測與趨勢分析
  • 靜脈
  • 腦室內 (ICV)/脊髓內

第6章韓特氏症治療市場：最終用途的商業分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 最終用途細分儀表板
  • 2018-2030 年按最終用途分類的市場規模、預測與趨勢分析
  • 醫院
  • 專科診所
  • 其他

第7章韓特氏症治療市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd.
    • Abbott
    • Denali Therapeutics
    • Medtronic
    • Johnson &Johnson Services, Inc.
    • GSK Plc.
    • Bayer AG
    • Zimmer Biomet
    • Stryker Corporation
    • Homology Medicines, Inc.
    • Novartis AG
Product Code: GVR-2-68038-743-8

Hunter Syndrome Treatment Market Growth & Trends:

The global hunter syndrome treatment market size is expected to reach a value of USD 1.78 billion by 2030, expanding at a CAGR of 5.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet needs, robust pipeline, increasing awareness about this rare disease and growing R&D activities for the development of novel therapies are expected to drive market growth over the forecast period.

Hunter syndrome, also referred as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by the missing or malfunctioning iduronate-2-sulfatase enzyme. According to the data published by the National Institute of Neurological Disorders and Stroke, MPS II syndrome occurs in around 1 in every 100,000 to 150,000 male births.

Presently, there are no approved curative therapies for the treatment of Hunter syndrome. The available treatment options such as enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are focused on providing symptomatic relief and management of complications associated with disease progression. Shire plc's Elaprase (idursulfase) is the only key drug available for the treatment of Hunter syndrome worldwide, with GC Pharma's Hunterase (idursulfase beta) being approved only in South Korea.

Key players are focused on extensive R&D activities for product development and gaining approval as novel therapies. Launch of such novel therapies in the near future is expected to significantly fuel the Hunter syndrome treatment market growth. For instance, in May 2018, REGENXBIO Inc. received the U.S. FDA's Fast Track designation for its novel drug candidate RGX-121, indicated for the disease treatment.

Hunter Syndrome Treatment Market Report Highlights:

  • The intravenous segment led the market and accounted for the largest revenue share of 72.3% in 2024 attributed to its established effectiveness in delivering enzyme replacement therapies (ERT).
  • Enzyme replacement therapy (ERT) led the market and accounted for the largest revenue share of 57.3% in 2024 driven by its ability to address the deficiency of the enzyme iduronate-2-sulfatase.
  • Hospitals held the dominant position in the market, accounting for the largest revenue share of 63.1% in 2024 attributed to their capacity to provide comprehensive care and advanced medical resources.
  • North America hunter syndrome treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to a combination of advanced healthcare infrastructure and increasing awareness of rare diseases.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Technology
    • 1.2.3. Test
    • 1.2.4. Type
    • 1.2.5. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hunter Syndrome Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Hunter Syndrome Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Enzyme Replacement Therapy (ERT)
    • 4.4.1. Enzyme Replacement Therapy (ERT) Market, 2018 - 2030 (USD Million)
  • 4.5. Hematopoietic Stem Cell Transplant (HSCT)
    • 4.5.1. Hematopoietic Stem Cell Transplant (HSCT) Market, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Hunter Syndrome Treatment Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Intravenous Market, 2018 - 2030 (USD Million)
  • 5.5. Intracerebroventricular (ICV)/ Intrathecal
    • 5.5.1. Intracerebroventricular (ICV)/Intrathecal Market, 2018 - 2030 (USD Million)

Chapter 6. Hunter Syndrome Treatment Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Hunter Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework
      • 7.4.2.3. Competitive insights
      • 7.4.2.4. U.S. hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework
      • 7.4.3.3. Competitive insights
      • 7.4.3.4. Canada hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework
      • 7.4.4.3. Competitive insights
      • 7.4.4.4. Mexico hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework
      • 7.5.2.3. Competitive insights
      • 7.5.2.4. UK hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework
      • 7.5.3.3. Competitive insights
      • 7.5.3.4. Germany hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework
      • 7.5.4.3. Competitive insights
      • 7.5.4.4. France hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework
      • 7.5.5.3. Competitive insights
      • 7.5.5.4. Italy hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework
      • 7.5.6.3. Competitive insights
      • 7.5.6.4. Spain hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework
      • 7.5.7.3. Competitive insights
      • 7.5.7.4. Norway hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework
      • 7.5.8.3. Competitive insights
      • 7.5.8.4. Denmark hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Regulatory framework
      • 7.5.9.3. Competitive insights
      • 7.5.9.4. Sweden hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework
      • 7.6.2.3. Competitive insights
      • 7.6.2.4. Japan hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework
      • 7.6.3.3. Competitive insights
      • 7.6.3.4. China hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework
      • 7.6.4.3. Competitive insights
      • 7.6.4.4. India hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework
      • 7.6.5.3. Competitive insights
      • 7.6.5.4. South Korea hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework
      • 7.6.6.3. Competitive insights
      • 7.6.6.4. Australia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework
      • 7.6.7.3. Competitive insights
      • 7.6.7.4. Thailand hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework
      • 7.7.2.3. Competitive insights
      • 7.7.2.4. Brazil hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework
      • 7.7.3.3. Competitive insights
      • 7.7.3.4. Argentina hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Hunter Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework
      • 7.8.2.3. Competitive insights
      • 7.8.2.4. South Africa hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework
      • 7.8.3.3. Competitive insights
      • 7.8.3.4. Saudi Arabia hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework
      • 7.8.4.3. Competitive insights
      • 7.8.4.4. UAE hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Regulatory framework
      • 7.8.5.3. Competitive insights
      • 7.8.5.4. Kuwait hunter syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial performance
      • 8.5.1.3. Type benchmarking
      • 8.5.1.4. Strategic initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial performance
      • 8.5.2.3. Type benchmarking
      • 8.5.2.4. Strategic initiatives
    • 8.5.3. Abbott
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial performance
      • 8.5.3.3. Type benchmarking
      • 8.5.3.4. Strategic initiatives
    • 8.5.4. Denali Therapeutics
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial performance
      • 8.5.4.3. Type benchmarking
      • 8.5.4.4. Strategic initiatives
    • 8.5.5. Medtronic
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial performance
      • 8.5.5.3. Type benchmarking
      • 8.5.5.4. Strategic initiatives
    • 8.5.6. Johnson & Johnson Services, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial performance
      • 8.5.6.3. Type benchmarking
      • 8.5.6.4. Strategic initiatives
    • 8.5.7. GSK Plc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial performance
      • 8.5.7.3. Type benchmarking
      • 8.5.7.4. Strategic initiatives
    • 8.5.8. Bayer AG
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial performance
      • 8.5.8.3. Type benchmarking
      • 8.5.8.4. Strategic initiatives
    • 8.5.9. Zimmer Biomet
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial performance
      • 8.5.9.3. Type benchmarking
      • 8.5.9.4. Strategic initiatives
    • 8.5.10. Stryker Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial performance
      • 8.5.10.3. Type benchmarking
      • 8.5.10.4. Strategic initiatives
    • 8.5.11. Homology Medicines, Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial performance
      • 8.5.11.3. Type benchmarking
      • 8.5.11.4. Strategic initiatives
    • 8.5.12. Novartis AG
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial performance
      • 8.5.12.3. Type benchmarking
      • 8.5.12.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Hunter Syndrome Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 7 North America Hunter Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 North America Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 U.S. Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 U.S. Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 14 Canada Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Canada Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 17 Mexico Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Europe Hunter Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 Europe Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 UK Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 UK Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 UK Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 27 Germany Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Germany Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 France Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 France Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 France Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Italy Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Italy Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 36 Spain Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Spain Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 Norway Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 Norway Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Norway Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 42 Denmark Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 43 Denmark Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44 Denmark Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Sweden Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Sweden Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Hunter Syndrome Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Japan Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Japan Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 55 China Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 56 China Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 China Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 58 India Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 59 India Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 India Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Australia Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Australia Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 64 South Korea Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 South Korea Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 67 Thailand Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Thailand Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 70 Latin America Hunter Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Latin America Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Brazil Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Brazil Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 77 Argentina Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 79 Argentina Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Hunter Syndrome Treatment Market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 84 South Africa Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 90 UAE Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 UAE Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Hunter Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Hunter Syndrome Treatment Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Hunter Syndrome Treatment Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Hunter Syndrome Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Segment outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Hunter syndrome treatment market dynamics
  • Fig. 13 Hunter syndrome treatment market: Porter's five forces analysis
  • Fig. 14 Hunter syndrome treatment market: PESTLE analysis
  • Fig. 15 Hunter syndrome treatment market: Type segment dashboard
  • Fig. 16 Hunter syndrome treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Enzyme replacement therapy (ERT) market, 2018 - 2030 (USD Million)
  • Fig. 18 Hematopoietic stem cell transplant (HSCT) market, 2018 - 2030 (USD Million)
  • Fig. 19 Others market, 2018 - 2030 (USD Million)
  • Fig. 20 Hunter syndrome treatment market: Route of Administration segment dashboard
  • Fig. 21 Hunter syndrome treatment market: Route of Administration market share analysis, 2024 & 2030
  • Fig. 22 Intravenous market, 2018 - 2030 (USD Million)
  • Fig. 23 Intracerebroventricular (ICV)/Intrathecal market, 2018 - 2030 (USD Million)
  • Fig. 24 Hunter syndrome treatment market: End use segment dashboard
  • Fig. 25 Hunter syndrome treatment market: End use market share analysis, 2024 & 2030
  • Fig. 26 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 27 Specialty clinics laboratories market, 2018 - 2030 (USD Million)
  • Fig. 28 Others market, 2018 - 2030 (USD Million)
  • Fig. 29 Hunter syndrome treatment market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Europe hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Asia Pacific hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 Latin America hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 MEA hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 Kuwait Key country dynamicss
  • Fig. 82 Kuwait hunter syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework